The abstract presented at the 2021 ASCO Annual Conference is a study synthesis of the clinical performance of the CE-IVD molecular test to assess the gemcitabine response in advanced pancreatic cancer.
Within the framework of the SME Instrument-Phase 1 call for projects, Europe provided a financial support to ACOBIOM in order to evaluate the costs of the current management of pancreatic cancer in France. This study will confirm the sale forecasts of the GemciTest in France and in Europe.
Produced by DNA, RNA is among the least known constituents of the life sciences and the least cited in publications, communications or media. RNA is delicate to use by technicians and always enigmatic for most scientists.
A scientific publication in Cancers, a peer reviewed scientific journal, presents the capabilities of Acobiom’s GemciTest® to identify the pancreatic cancer patients who are most likely to benefit from gemcitabine-based treatment as the first approach.
In a recent study, ACOBIOM, in partnering with the Jerome Lejeune Institute, characterized molecular mechanisms that could help to better understand the decreased incidence of Breast Cancer in women with Down Syndrome (Trisomy 21).
GemciTest®, an in-vitro diagnostic that predicts the patient’s response to one of the therapies used to treat pancreatic cancer, benefits now from CE marking, which means it complies with current European regulations in force. Acobiom develops innovative blood diagnostics in the field of precision medicine. These tests, based on liquid biopsies (blood), aim to give… Read more
On next November 21, 2019, the World Pancreatic Cancer Day 2019 will be organized. Key information about pancreatic cancer Pancreatic cancer is one of the world’s deadliest cancers. This cancer develops when cells of the organs grow out of control, developing a tumor. The pancreas is a gland located deep in the abdomen, between the… Read more
Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated with a clinical response to a specific therapy needs a tremendous combination of a scientific expertise, a biomolecular know-how, and a panel of bioinformatics and… Read more